New combo therapy aims to knock back recurrent prostate cancer

NCT ID NCT03902951

Ongoing Disease control Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial is testing whether combining antiandrogen drugs (leuprolide, apalutamide, abiraterone) with precise radiation (SBRT) can control prostate cancer that has come back and spread to a few other spots in the body. The study enrolls 28 men whose cancer has 1-5 visible metastases. The main goal is to see how many achieve a very low PSA level (<0.05 ng/mL), which would indicate strong disease control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Abiraterone acetate, apalutamide, leuprolide acetate, and stereotactic body radiation therapy (SBRT)
What this could lead to: If successful, this combination could offer a way to control recurrent prostate cancer that has spread to a few sites, potentially delaying the need for stronger treatments.
What could go wrong: This is a small, early-phase trial with only 28 participants, so results may not apply to everyone. The drugs can cause side effects like fatigue, hot flashes, and liver issues, and the radiation may damage nearby healthy tissue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate adenocarcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PROSTATE ADENOCARCINOMA PROSTATE ADENOCARCINOMA WITH FOCAL NEUROENDOCRINE DIFFERENTIATION RECURRENT PROSTATE CARCINOMA STAGE IVB PROSTATE CANCER AJCC V8

Contacts and locations

Locations

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.